The LAG-3 Market has expanded from a small immunology niche into a central focus for oncology, immuno-oncology combinations, and autoimmune research. Growing interest beyond PD-1/PD-L1 checkpoints is fueled by stronger biological understanding, more active clinical programs, and early evidence that LAG-3 therapies can improve outcomes when used with other treatments. Scientific and...